文献速递呼吸衰竭与机械通气儿科与产科急症重症综合管理与镇静镇痛

儿童坏死性肺炎:三级中心的临床特征、微生物学、治疗与结局

Pediatric necrotizing pneumonia: Clinical features, microbiology, management, and outcomes in the tertiary center.
PubMed 文献 · Am J Emerg Med · 2026-07-09
一句话结论儿童肺炎抗生素治疗72小时后仍持续发热、呼吸衰竭或迁延不愈需警惕坏死性肺炎,诊断依赖影像,以抗肺炎链球菌和金黄色葡萄球菌的长程静脉抗生素为主,必要时外科干预。

该回顾性研究在三级中心963例住院儿童肺炎中识别出15例坏死性肺炎(1.6%),中位年龄3岁,入院时73.3%存在呼吸衰竭(SpO2<94%)。肺炎链球菌(53.3%)和金黄色葡萄球菌(13.3%)为主要病原,46.7%为混合感染,PCR检出率高于传统培养(64.7% vs 20.3%)。73.3%合并胸腔积液或脓胸,53.3%需外科干预(以VATS加胸腔引流为主)。初始抗生素以β-内酰胺类联合万古霉素(60 mg/kg/day)为主,60.0%需升级至80 mg/kg/day,住院和抗生素疗程中位分别为25天和28天,总生存率93.3%。

要点

  • 儿童肺炎抗生素治疗72小时后持续发热、呼吸衰竭或病情迁延,应评估坏死性肺炎等并发症。
  • 诊断依赖胸部影像(CXR、超声或CT),胸腔积液或脓胸见于73.3%的坏死性肺炎患儿。
  • 病原以肺炎链球菌(53.3%)和金黄色葡萄球菌(13.3%)为主,46.7%为混合感染。
  • 初始抗生素多为β-内酰胺类联合万古霉素60 mg/kg/day,60.0%需升级至80 mg/kg/day,需行治疗药物监测。
  • 53.3%需外科干预(VATS加胸腔引流),持续感染、显著胸腔积液或广泛坏死导致脓毒症/呼吸衰竭失控时考虑。

适用人群与场景

  • 三级中心住院的儿童肺炎患者中诊断的坏死性肺炎,中位年龄3岁。

诊断标准与关键阈值

  • 诊断基于临床表现和影像学发现(胸部X线、超声或CT)。
  • 原文未提及具体的影像学界值或评分标准。

处置流程与药物剂量

  • 第一步:对肺炎抗生素治疗72小时后持续发热、呼吸衰竭或迁延不愈者,行胸部影像(CXR、超声或CT)评估并发症。
  • 第二步:初始抗感染以β-内酰胺类联合万古霉素60 mg/kg/day为主,60.0%患儿需升级至80 mg/kg/day,万古霉素需行治疗药物监测。
  • 第三步:针对肺炎链球菌和金黄色葡萄球菌使用长程静脉抗生素,中位抗生素疗程28天。
  • 第四步:持续感染、显著胸腔积液或广泛坏死导致脓毒症或呼吸衰竭失控时,行外科干预(清创、胸腔引流),以VATS加胸腔引流为主。

红旗征与不能漏的情况

  • 入院时呼吸衰竭(SpO2<94%)见于73.3%的坏死性肺炎患儿,需呼吸支持。
  • 胸腔积液或脓胸见于73.3%的患儿,需评估外科干预。
  • 持续感染、显著胸腔积液或广泛坏死导致脓毒症或呼吸衰竭失控时,需外科干预。

研究设计与关键结果

  • 回顾性研究,三级中心963例儿童肺炎住院中15例(1.6%)诊断为坏死性肺炎,中位年龄3岁。
  • 入院时73.3%存在呼吸衰竭(SpO2<94%),全部接受呼吸支持:有创机械通气40.0%、NCPAP 33.3%、低流量鼻导管吸氧26.7%。
  • 病原:肺炎链球菌53.3%、金黄色葡萄球菌13.3%、混合感染46.7%;PCR检出率64.7%高于传统培养20.3%。
  • 胸腔积液或脓胸73.3%,外科干预53.3%(以VATS加胸腔引流为主)。
  • 初始抗生素以β-内酰胺类联合万古霉素60 mg/kg/day为主,60.0%升级至80 mg/kg/day;住院和抗生素疗程中位25天和28天;总生存率93.3%,1例死于脓毒症休克和多器官衰竭;CRP升高是唯一与治疗结局显著相关的因素(p=0.011)。

证据类型、等级与局限

  • 回顾性研究,单中心,样本量小(15例),原文未提及证据等级。
  • 局限:回顾性设计、单中心、样本量小。

对床旁实践的改变

  • 儿童肺炎抗生素治疗72小时后仍持续发热、呼吸衰竭或迁延不愈,应行胸部影像评估坏死性肺炎等并发症。
  • 坏死性肺炎患儿需长程静脉抗生素覆盖肺炎链球菌和金黄色葡萄球菌,万古霉素使用60-80 mg/kg/day并行治疗药物监测。
  • 合并显著胸腔积液、持续感染或广泛坏死导致脓毒症/呼吸衰竭失控时,应尽早考虑外科干预(VATS加胸腔引流)。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: Pediatric necrotizing pneumonia (PNP) is a rare but life-threatening complication of pneumonia. This study aimed to describe the clinical characteristics, paraclinical features, interventional treatments, and outcomes of PNP.

METHODS: This was a retrospective study of PNP identified from hospitalized pneumonia cases at a tertiary center. Diagnosis was based on clinical presentation and imaging findings (CXR, ultrasound, or CT). Demographic, clinical, microbiological, laboratory, treatment, and outcome data were analyzed. Associations between clinical variables and outcomes were analyzed, with statistical significance set at p < 0.05.

RESULTS: Among 963 pediatric pneumonia hospitalizations, 15 patients (1.6%) were diagnosed with PNP, with a median age of 3 years. At admission, respiratory failure (SpO2 < 94%) was present in 73.3% of patients. Respiratory support was administered to all patients and categorized according to the highest level of support received: invasive mechanical ventilation (40.0%), nasal continuous positive airway pressure (NCPAP) (33.3%), and low-flow oxygen via nasal cannula (26.7%); no patients received high-flow nasal cannula (HFNC) or bilevel positive airway pressure (BiPAP). No patients received corticosteroids or nebulized therapy before admission, whereas corticosteroids and nebulized therapy were administered during hospitalization in 13.3% and 20.0% of patients, respectively. Streptococcus pneumoniae was the predominant pathogen (53.3%), followed by Staphylococcus aureus (13.3%), and polymicrobial infections were identified in 46.7% of cases. PCR showed a higher pathogen detection rate than conventional culture (64.7% vs. 20.3%), particularly in respiratory and pleural specimens. Pleural effusion or empyema was identified in 73.3% of patients, and surgical intervention was required in 53.3%, primarily involving video-assisted thoracoscopic surgery (VATS) with pleural drainage. Initial antimicrobial therapy mainly consisted of β-lactams combined with vancomycin (60 mg/kg/day), with dose escalation to 80 mg/kg/day required in 60.0% of patients. Median durations of hospitalization and antibiotic therapy were 25 and 28 days, respectively. Overall survival was 93.3%, with one death attributed to septic shock and multi-organ failure. Elevated C-reactive protein was the only factor significantly associated with treatment outcome (p = 0.011).

CONCLUSION: Persistent fever, respiratory failure, or prolonged pneumonia after 72 h of antibiotics warrants evaluation for complications. Diagnosis relies on chest imaging (CXR, ultrasound, or CT), with prolonged intravenous antibiotics targeting Streptococcus pneumoniae and Staphylococcus aureus. Therapeutic drug monitoring is essential for vancomycin. Surgical intervention (debridement, pleural drainage) is indicated for persistent infection, significant pleural effusion, or extensive necrosis leading to uncontrolled sepsis or respiratory failure.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Le TVT, Pham EC, Do TTH, et al. Pediatric necrotizing pneumonia: Clinical features, microbiology, management, and outcomes in the tertiary center. Am J Emerg Med. 2026. PMID: 42456543. doi:10.1016/j.ajem.2026.07.010

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。